These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 12714523)

  • 1. Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma.
    Honeychurch J; Glennie MJ; Johnson PW; Illidge TM
    Blood; 2003 Aug; 102(4):1449-57. PubMed ID: 12714523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody.
    Tutt AL; O'Brien L; Hussain A; Crowther GR; French RR; Glennie MJ
    J Immunol; 2002 Mar; 168(6):2720-8. PubMed ID: 11884438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells.
    Honeychurch J; Glennie MJ; Illidge TM
    Cancer Res; 2005 Aug; 65(16):7493-501. PubMed ID: 16103104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors.
    Tutt AL; French RR; Illidge TM; Honeychurch J; McBride HM; Penfold CA; Fearon DT; Parkhouse RM; Klaus GG; Glennie MJ
    J Immunol; 1998 Sep; 161(6):3176-85. PubMed ID: 9743386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb.
    Ito D; Ogasawara K; Iwabuchi K; Inuyama Y; Onoé K
    J Immunol; 2000 Feb; 164(3):1230-5. PubMed ID: 10640735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4 T cell-mediated alloresistance to fully MHC-mismatched allogeneic bone marrow engraftment is dependent on CD40-CD40 ligand interactions, and lasting T cell tolerance is induced by bone marrow transplantation with initial blockade of this pathway.
    Ito H; Kurtz J; Shaffer J; Sykes M
    J Immunol; 2001 Mar; 166(5):2970-81. PubMed ID: 11207246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic effect of agonistic CD40 monoclonal antibody combined with CTL on hu-SCID mouse B lymphoma model].
    Zhou H; Xi H; Ma QR; Chen C; Zhang F; Zhang XG; Gu ZJ
    Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):181-5. PubMed ID: 17649632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CTL-promoting effects of CD40 stimulation outweigh B cell-stimulatory effects resulting in B cell elimination and disease improvement in a murine model of lupus.
    Puliaev R; Puliaeva I; Welniak LA; Ryan AE; Haas M; Murphy WJ; Via CS
    J Immunol; 2008 Jul; 181(1):47-61. PubMed ID: 18566369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.
    White AL; Dou L; Chan HT; Field VL; Mockridge CI; Moss K; Williams EL; Booth SG; French RR; Potter EA; Butts C; Al-Shamkhani A; Cragg MS; Verbeek JS; Johnson PW; Glennie MJ; Beers SA
    J Immunol; 2014 Aug; 193(4):1828-35. PubMed ID: 25024386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell activation induced by anti-CD3 x anti-B-cell lymphoma monoclonal antibody is enhanced by pretreatment of lymphoma cells with soluble CD40 ligand.
    Wooldridge JE; Dahle CE; Weiner GJ
    Cancer Immunol Immunother; 1997; 45(3-4):174-9. PubMed ID: 9435867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioimmunotherapy in the pi-BCL1 B cell lymphoma model: efficacy depends on more than targeted irradiation alone.
    Illidge T; Honeychurch J; Vandersteen A; Cragg M
    Cancer Biother Radiopharm; 2000 Dec; 15(6):581-91. PubMed ID: 11190490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined anti-CD40 conditioning and well-timed immunization prolongs CD8+ T cell accumulation and control of established brain tumors.
    Ryan CM; Staveley-O'Carroll K; Schell TD
    J Immunother; 2008; 31(9):906-20. PubMed ID: 18832997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble antigen and CD40 triggering are sufficient to induce primary and memory cytotoxic T cells.
    Lefrançois L; Altman JD; Williams K; Olson S
    J Immunol; 2000 Jan; 164(2):725-32. PubMed ID: 10623816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral interleukin-2/agonist CD40 antibody drives CD4+ -independent resolution of treated-tumors and CD4+ -dependent systemic and memory responses.
    Jackaman C; Nelson DJ
    Cancer Immunol Immunother; 2012 Apr; 61(4):549-60. PubMed ID: 22002241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner.
    Iwakoshi NN; Mordes JP; Markees TG; Phillips NE; Rossini AA; Greiner DL
    J Immunol; 2000 Jan; 164(1):512-21. PubMed ID: 10605049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help.
    French RR; Chan HT; Tutt AL; Glennie MJ
    Nat Med; 1999 May; 5(5):548-53. PubMed ID: 10229232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.
    van Mierlo GJ; Boonman ZF; Dumortier HM; den Boer AT; Fransen MF; Nouta J; van der Voort EI; Offringa R; Toes RE; Melief CJ
    J Immunol; 2004 Dec; 173(11):6753-9. PubMed ID: 15557168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined sublethal irradiation and agonist anti-CD40 enhance donor T cell accumulation and control of autochthonous murine pancreatic tumors.
    Ward-Kavanagh LK; Kokolus KM; Cooper TK; Lukacher AE; Schell TD
    Cancer Immunol Immunother; 2018 Apr; 67(4):639-652. PubMed ID: 29332158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation.
    French RR; Taraban VY; Crowther GR; Rowley TF; Gray JC; Johnson PW; Tutt AL; Al-Shamkhani A; Glennie MJ
    Blood; 2007 Jun; 109(11):4810-5. PubMed ID: 17311995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model.
    Williams EL; Dunn SN; James S; Johnson PW; Cragg MS; Glennie MJ; Gray JC
    Clin Cancer Res; 2013 Jul; 19(13):3545-55. PubMed ID: 23649004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.